Examinations

ANDA patent litigation: what does the technical expert compare in a Hatch-Waxman case?

A generic drug company that files an abbreviated new drug application with a Paragraph IV certification infringes the patent by the filing itself, under 35 U.S.C. 271(e)(2). The case is tried before the generic reaches pharmacies. The accused product is the drug described in the ANDA, and the technical expert maps each claim element to the formulation, the specifications and the manufacturing process in that application.

Hands compare two plain white tablets beside a blank bottle and a binder

Why is filing an ANDA an act of infringement?

Because 35 U.S.C. 271(e)(2) makes it one. Submitting an ANDA for a drug claimed in a patent, or for a drug whose use is claimed in a patent, infringes before any generic is sold.

Ordinary infringement under 35 U.S.C. 271(a) needs a commercial act: "whoever without authority makes, uses, offers to sell, or sells any patented invention, within the United States or imports into the United States any patented invention during the term of the patent therefor, infringes the patent." A company that has prepared and filed an application has not yet sold anything.

Section 271(e)(1) protects the preparatory work. Making, using, selling or importing a patented invention is not infringement when it is done "solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use, or sale of drugs or veterinary biological products."

Section 271(e)(2) then turns the filing into the act of infringement. It covers the submission of "an application under section 505(j) of the Federal Food, Drug, and Cosmetic Act or described in section 505(b)(2) of such Act for a drug claimed in a patent or the use of which is claimed in a patent." Section 505(j) is the ANDA provision, codified at 21 U.S.C. 355(j).

The result is a patent case with no product on the market. The patent owner proves infringement by what the generic company asked FDA to approve, and the generic company proves invalidity or non-infringement on the same record. Both sides need a technical expert who can read the application as if it were a product.

What is a Paragraph IV certification?

One of four patent certifications listed in 21 U.S.C. 355(j)(2)(A)(vii). It states that a listed patent is invalid or will not be infringed by the manufacture, use or sale of the generic drug.

The statute gives the applicant four choices for the patents on the reference drug. The applicant certifies "that such patent information has not been filed," "that such patent has expired," "of the date on which such patent will expire," or "that such patent is invalid or will not be infringed by the manufacture, use, or sale of the new drug."

The fourth choice is subclause (IV), and the industry name Paragraph IV comes from it. A certification under subclause (III) names the expiration date. A certification under subclause (IV) challenges the patent, and the statute attaches to it a duty to notify the patent owner and a deadline for suit.

The certification is made patent by patent. One generic application can therefore lead to a suit on several patents, some claiming the drug and some claiming a use of it, which are the two kinds of claims named in 271(e)(2). The technical expert works through each asserted claim separately. A use claim calls for a different comparison than a claim to the drug itself.

What must the Paragraph IV notice letter contain?

A detailed statement of the factual and legal basis of the applicant's opinion. FDA rules require a full and detailed explanation for each claim alleged not infringed and for each claim alleged invalid or unenforceable.

The timing is set by statute. Under 21 U.S.C. 355(j)(2)(B)(ii)(I), the applicant gives notice "not later than 20 days after the date of the postmark on the notice with which the Secretary informs the applicant" that the application has been received. FDA's rule, 21 CFR 314.95(b)(1), says the applicant sends the notice on or after the date it receives a paragraph IV acknowledgment letter from FDA and not later than 20 days after the date of the postmark.

The notice goes to "each owner of the patent that is the subject of the certification," among others listed in 314.95(a). Under 355(j)(2)(B)(iv)(II), it must "include a detailed statement of the factual and legal basis of the opinion of the applicant" that the patent is invalid or will not be infringed. Section 314.95(c) adds required items, among them the ANDA number and the number and expiration date of each listed patent.

Paragraph (c)(7) is the part the technical expert reads first. For each claim alleged not to be infringed, the notice gives "a full and detailed explanation of why the claim is not infringed." For each claim alleged to be invalid or unenforceable, it gives "a full and detailed explanation of the grounds supporting the allegation."

The letter is the generic company's first written position, claim by claim. The patent owner's expert checks each explanation against the claim language and against the formulation the application describes, and the generic company's expert later has to stay with positions that can be defended at trial.

What happens if the patent owner sues within 45 days?

FDA approval of the generic is postponed until a thirty-month period from receipt of the notice runs out, unless the district court decides before then that the patent is invalid or not infringed.

21 U.S.C. 355(j)(5)(B)(iii) ties the approval date to a suit brought "before the expiration of 45 days after the date on which the notice described in paragraph (2)(B) is received." With such a suit pending, approval becomes effective "upon the expiration of the thirty-month period beginning on the date of the receipt of the notice."

The same clause moves the date when the court rules first: approval follows the decision "if before the expiration of such period the district court decides that the patent is invalid or not infringed."

The postponement depends on a suit filed within the 45 days. Contentions, claim construction, expert reports and trial are all scheduled against the thirty months, so the expert timetable in an ANDA case is set by the statute as much as by the judge.

What is the accused product in an ANDA case?

The drug the ANDA describes, which is what the applicant will likely market if approved. The expert compares every claim element with the formulation, specifications and process in the application.

In Allergan, Inc. v. Alcon Laboratories, Inc., 324 F.3d 1322 (Fed. Cir. 2003), the Federal Circuit restated how a 271(e)(2) claim is tried. The question "must focus on what the ANDA applicant will likely market if its application is approved," and "a court must employ a traditional infringement analysis, focusing on all of the elements of infringement."

In the District of New Jersey, Local Patent Rule 3.6 puts the application in the patent owner's hands at the start. On the date a party answers, moves or otherwise responds to the complaint, each party that is an ANDA filer produces its entire ANDA or NDA underlying the case.

The comparison follows the claim. A composition claim is read against the ingredients and amounts the application specifies. A process claim is read against the manufacturing description. A use claim is read against the uses for which approval is sought. Each element is marked as found on a cited page of the application, or as absent.

Samples and test batches are the second source. When the expert tests them, the report names the batch and the method, because Rule 26(a)(2)(B)(ii) of the Federal Rules of Civil Procedure requires the report to state "the facts or data considered by the witness in forming" the opinions.

When are contentions due in a Hatch-Waxman case in New Jersey?

Under Local Patent Rule 3.6, the generic company produces its ANDA when it first responds to the complaint. Asserted claims, invalidity and non-infringement contentions follow 7 and 30 days after the initial scheduling conference.

Rule 3.6 applies to all patents subject to a Paragraph IV certification and takes precedence over conflicting provisions of Rules 3.1 through 3.5. The version posted by the court states that the rules were adopted on December 11, 2008, took effect on January 1, 2009, and were amended on March 18, 2011, October 4, 2011, June 19, 2013 and February 1, 2017.

Within 7 days after the initial scheduling conference, the patent owner serves a Disclosure of Asserted Claims listing each claim said to be infringed and the subsections of 35 U.S.C. 271 that apply. Within 30 days after the conference, the generic company serves its invalidity contentions with the disclosures of Rule 3.3 and the documents of Rule 3.4(b) and (c), and its non-infringement contentions with a claim chart.

The non-infringement chart identifies, for each claim, which limitations are literally absent from the ANDA or NDA product, and it comes with the documents and things the ANDA filer intends to rely on. The patent owner answers with infringement contentions within 45 days after the non-infringement contentions, limited to the claims already asserted, and responds to the invalidity contentions within 45 days after receiving them.

The order differs from an ordinary patent case. Here the generic company states its non-infringement position first, element by element, and the patent owner's expert builds the infringement chart in answer to it. Rule 3.6(j) also requires a party with a pending ANDA to tell FDA about any motion for injunctive relief within 3 business days and to give the patent owner copies of its FDA correspondence about the ANDA within 7 days.

Can a method-of-use patent be asserted against an ANDA for a use the generic does not seek?

In Allergan v. Alcon (2003) the Federal Circuit said no. The generics sought approval to lower intraocular pressure, while the patents claimed other uses of brimonidine that FDA had not approved.

The drug was brimonidine. One patent claimed "a method of protecting the optic nerve and retina of a mammal comprising administering to said mammal" the drug, the other "a method of providing neural protection to a mammal comprising administering to said mammal" the drug. The court found: "Neither Alcon nor B & L sought FDA approval for the methods of using brimonidine claimed in the '415 and '741 patents."

Following Warner-Lambert Co. v. Apotex Corp., decided on January 16, 2003, the per curiam opinion held that "a method of use patent holder may not sue an ANDA applicant for induced infringement of its patent" where the applicant is not seeking FDA approval for the use claimed in the patent and that use is not FDA-approved. Summary judgment for the generic companies was affirmed.

The separate opinions questioned the rule. Judge Schall, joined by Judge Clevenger, wrote "to express my respectful disagreement with the decision of the court in Warner-Lambert" and would have found the inducement claim cognizable under 271(e)(2). Judge Linn concurred in the judgment and wrote that Warner-Lambert went beyond the plain text of the statute.

For a use claim, the expert therefore starts with the uses the application asks FDA to approve. The claimed method is compared with the indications sought in the ANDA, and a use that the application does not seek is outside the 271(e)(2) comparison as Allergan described it.

What can the court order if the ANDA infringes?

Under 35 U.S.C. 271(e)(4), an approval date no earlier than patent expiration, an injunction against commercial activity, and damages only after commercial manufacture, use, offer to sell, sale or importation.

Subparagraph (A) directs that "the court shall order the effective date of any approval of the drug or veterinary biological product involved in the infringement to be a date which is not earlier than the date of the expiration of the patent which has been infringed."

Subparagraph (B) permits an injunction "to prevent the commercial manufacture, use, offer to sell, or sale within the United States or importation into the United States of an approved drug." Subparagraph (C) limits money: damages or other monetary relief "may be awarded against an infringer only if there has been commercial manufacture, use, offer to sell, or sale within the United States or importation into the United States of an approved drug."

Before the generic launches, the dispute is about the approval date and an injunction, and the technical experts carry the case. A damages expert has work under (C) only after commercial activity with the approved drug.

What does the technical expert need from the case file?

The notice letter with its detailed statement, the produced ANDA, the asserted claims and both sides' contentions, any samples and test data, and the generic company's FDA correspondence about the application.

The notice letter and the application come first: the letter states the generic company's reasons claim by claim, and the application describes the product the court will compare with the claims. Under New Jersey Rule 3.6(j), FDA correspondence about the ANDA reaches the patent owner within 7 days after it is sent or received, so changes to the application during the case reach the expert as well.

The report itself follows Rule 26(a)(2)(B): "a complete statement of all opinions the witness will express and the basis and reasons for them," the facts or data considered, exhibits, the expert's qualifications with publications from the previous 10 years, the cases in which the expert testified in the previous 4 years, and the compensation. Facts, data and assumptions supplied by the attorney are discoverable under Rule 26(b)(4)(C), and a report answering the other side's expert on the same subject is due within 30 days under Rule 26(a)(2)(D)(ii) unless the court sets another schedule.

Admissibility is decided under Rule 702. Since the 2023 amendment, the proponent must show the court that it is more likely than not that the testimony rests on sufficient facts or data, comes from reliable principles and methods, and applies them reliably to the case. The committee note adds that "each expert opinion must stay within the bounds of what can be concluded from a reliable application of the expert's basis and methodology."

What does IAE do in a dispute over a generic drug patent?

An IAE expert prepares a report on infringement or validity, or a review of the opposing technical expert's report, for district court and PTAB cases. The document is issued in up to 5 business days.

The patent expertise page describes the infringement work as claim charts that map each claim element to the accused product, with equivalents tested element by element, and the validity work as a prior art search before the effective filing date with an obviousness analysis for a person of ordinary skill.

IAE chooses the expert by the technical field of the patent and confirms the patent, the asserted claims and the questions before work starts. The client sends the notice letter, the asserted patents and the parts of the ANDA it can share under the protective order. The secretariat confirms receipt the same day. Within one business day IAE confirms the format, the cost, the deadline and the expert from its registry, and the client approves the candidate and the CV. The signed PDF is issued in up to 5 business days, with a 48-hour rush for tight deadlines.

Every expert is a member of the public IAE registry, verifiable by Member ID or QR code, and states in the document that he or she has no interest in the outcome. A report is evidence that the court weighs with the other evidence, and neither IAE nor the expert guarantees the outcome. IAE is not a law firm and does not advise on case strategy.

Sources

Read also

All articles

Expert examinations

Ready to discuss your case?

Send the materials: the secretariat will confirm the format, cost, deadline and the specialist within one business day.

Expertise request

Received

Cost and timeline estimate

WorkReview of an opinion
TimelineUp to 5 business days
ExpertIAE registry member